|
1
|
Sun XH, Geg XL, Zhang J and Zhang C:
miRNA-646 suppresses osteosarcoma cell metastasis by downregulating
fibroblast growth factor 2 (FGF2). Tumour Biol. 36:2127–2134. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang J and Zhang W: New molecular insights
into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Han K, Zhao T, Chen X, Bian N, Yang T, Ma
Q, Cai C, Fan Q, Zhou Y and Ma B: microRNA-194 suppresses
osteosarcoma cell proliferation and metastasis in vitro and in vivo
by targeting CDH2 and IGF1R. Int J Oncol. 45:1437–1449. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun K and Lai EC: Adult-specific functions
of animal microRNAs. Nat Rev Genet. 14:535–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li X, Yang H, Tian Q, Liu Y and Weng Y:
Upregulation of microRNA-17-92 cluster associates with tumor
progression and prognosis in osteosarcoma. Neoplasma. 61:453–460.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang G, Shen N, Cheng L, Lin J and Li K:
Downregulation of miR-22 acts as an unfavorable prognostic
biomarker in osteosarcoma. Tumour Biol. 36:7891–7895. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pencheva N and Tavazoie SF: Control of
metastatic progression by microRNA regulatory networks. Nat Cell
Biol. 15:546–554. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Gao W, Hu F, Xu Z and Wang F:
MicroRNA-874 inhibits cell proliferation and induces apoptosis in
human breast cancer by targeting CDK9. FEBS Lett. 588:4527–4535.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang X, Tang J, Zhi X, Xie K, Wang W, Li
Z, Zhu Y, Yang L, Xu H and Xu Z: miR-874 functions as a tumor
suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway
in gastric cancer. Oncotarget. 6:1605–1617. 2015.PubMed/NCBI
|
|
10
|
Nohata N, Hanazawa T, Kikkawa N, Sakurai
D, Fujimura L, Chiyomaru T, Kawakami K, Yoshino H, Enokida H,
Nakagawa M, et al: Tumour suppressive microRNA-874 regulates novel
cancer networks in maxillary sinus squamous cell carcinoma. Br J
Cancer. 105:833–841. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kesanakurti D, Maddirela DR, Chittivelu S,
Rao JS and Chetty C: Suppression of tumor cell invasiveness and in
vivo tumor growth by microRNA-874 in non-small cell lung cancer.
Biochem Biophys Res Commun. 434:627–633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nohata N, Hanazawa T, Kinoshita T, Inamine
A, Kikkawa N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Okamoto
Y and Seki N: Tumour-suppressive microRNA-874 contributes to cell
proliferation through targeting of histone deacetylase 1 in head
and neck squamous cell carcinoma. Br J Cancer. 108:1648–1658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang B, Li Z, Zhang W, Wang H, Zhi X,
Feng J, Chen Z, Zhu Y, Yang L, Xu H and Xu Z: miR-874 inhibits cell
proliferation, migration and invasion through targeting aquaporin-3
in gastric cancer. J Gastroenterol. 49:1011–1025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang LQ, Sun SL, Li WY, Feng Z, Xu XY,
Zhuang QS and Fang J: Decreased expression of tumor suppressive
miR-874 and its clinical significance in human osteosarcoma. Genet
Mol Res. 14:18315–18324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garriga J, Bhattacharya S, Calbó J,
Marshall RM, Truongcao M, Haines DS and Graña X: CDK9 is
constitutively expressed throughout the cell cycle, and its
steady-state expression is independent of SKP2. Mol Cell Biol.
23:5165–5173. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gordon V, Bhadel S, Wunderlich W, Zhang J,
Ficarro SB, Mollah SA, Shabanowitz J, Hunt DF, Xenarios I, Hahn WC,
et al: CDK9 regulates AR promoter selectivity and cell growth
through serine 81 phosphorylation. Mol Endocrinol. 24:2267–2280.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krystof V, Baumli S and Fürst R:
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
Curr Pharm Des. 18:2883–2890. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mitra P, Yang RM, Sutton J, Ramsay RG and
Gonda TJ: CDK9 inhibitors selectively target estrogen
receptor-positive breast cancer cells through combined inhibition
of MYB and MCL-1 expression. Oncotarget. 23:9069–9083. 2016.
|
|
20
|
Morales F and Giordano A: Overview of CDK9
as a target in cancer research. Cell Cycle. 15:519–527. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yin T, Lallena MJ, Kreklau EL, Fales KR,
Carballares S, Torrres R, Wishart GN, Ajamie RT, Cronier DM,
Iversen PW, et al: A novel CDK9 inhibitor shows potent antitumor
efficacy in preclinical hematologic tumor models. Mol Cancer Ther.
13:1442–1456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu X, Shi S, Lam F, Pepper C, Fischer PM
and Wang S: CDKI-71, a novel CDK9 inhibitor, is preferentially
cytotoxic to cancer cells compared to flavopiridol. Int J Cancer.
130:1216–1226. 2012. View Article : Google Scholar : PubMed/NCBI
|
